Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. [electronic resource]
Producer: 20090127Description: 2193-200 p. digitalISSN:- 1476-5551
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Asparaginase -- therapeutic use
- Child
- Child, Preschool
- Combined Modality Therapy
- Cyclophosphamide -- therapeutic use
- Cytarabine -- therapeutic use
- Daunorubicin -- therapeutic use
- Disease-Free Survival
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Infant
- Male
- Mercaptopurine -- therapeutic use
- Methotrexate -- therapeutic use
- Multivariate Analysis
- Neoplasm, Residual -- drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Predictive Value of Tests
- Prednisone -- therapeutic use
- Prognosis
- Prospective Studies
- Recurrence
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
- Survival Analysis
- Treatment Outcome
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.